René Bernards

1953 -

alma mater: Amszterdami Egyetem, Leideni Egyetem

foglalkozás: onkológus, egyetemi oktató, kutató

elnyert díj: Spinoza Prize, Akademiehoogleraren Prize, Fellow of the AACR Academy, EMBO Membership

René Bernards (born 4 January 1953) is a Dutch cancer researcher. He is professor of molecular carcinogenesis at Utrecht University and head of the section of molecular carcinogenesis at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis. Bernards is a winner of the 2005 Spinoza Prize. Source: Wikipedia (en)

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 188

Date

Title

Authors

2022-06-08

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant

Joana M Xavier, Matthew D Eldridge, Chong Sun, Ana Marreiros, René Bernards, Carlos Caldas, Suet-feung Chin, Ana Teresa Maia, Astrid Bosma, Lorenza Mittempergher
2021-06-09

Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability

Marit E Geijer, Kathiresan Selvam, Marvin van Toorn, Jeroen Demmers, Marcel A T M van Vugt, Hannes Lans, René Bernards, Jesper Qualmann Svejstrup, Jurgen A Marteijn, Arjan F Theil, Roel Janssen, Wim Vermeulen, Anja Raams, Adriaan B Houtsmuller
2021-06-23

Exploring liver cancer biology through functional genetic screens

René Bernards, Wenxin Qin
2021-03-05

Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells

Giulia De Conti, René Bernards
2020-06-22

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

João M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, Salo N Ooft, Lourdes Farré, Chelsea M Brideau, Emile E Voest, Olaf van Tellingen, Alberto Villanueva, René Bernards, Lodewyk F A Wessels
2020-10-05

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer

Haojie Jin, René Bernards
2019-04-18

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers

Floris H Groenendijk, René Bernards
2019-09-13

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma

René Bernards
2019-06-03

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities

Jean-Philippe Coppé, Ana Ruiz-Saenz, Christian Posch, Mark M Moasser, René Bernards, Daniel Peeper
2018-03-05

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma

René Bernards, Wenxin Qin
2018-04-18

Anti-cancer therapy: senescence is the new black.

René Bernards, Rodrigo Leite de Oliveira
2018-05-28

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

René Bernards, Niels de Wit, Samuel Gonçalves-Ribeiro, Ernest Nadal, Alberto Bardelli
2018-05-24

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

Evert Bosdriesz, René Bernards, Carlos Caldas
2018-01-23

phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer

René Bernards
2018-09-11

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival

Marcelo Sobral-Leite, Koen Van de Vijver, Magali Michaut, Hugo Horlings, Tesa M Severson, Anna Marie Mulligan, Nayana Weerasooriya, Joyce Sanders, Annuska Glas, Erik Hooijberg, René Bernards, Marleen Kok, Karina Elizabeth de Visser, Marjanka K Schmidt, Irene L Andrulis
2018-10-09

With great power comes great vulnerability

Rodrigo Leite de Oliveira, René Bernards, Liqin Wang
2018-05-15

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors

René Bernards, Hiroaki Itamochi
2017-05-31

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data

Andreas Reinisch, René Bernards, David L. Dill
2016-06-16

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

René Bernards, Josep Tabernero Caturla, Daniele Oddo, Ludovic Barault, Sabrina Arena, Alice Bartolini, Giovanni Crisafulli, Giorgio Corti, Giulia Siravegna, Andrea Sartore-Bianchi, Alberto Bardelli, Salvatore Siena, Federica Di Nicolantonio, Michela Buscarino
2016-03-02

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

René Bernards, Remco De Bree
2016-01-19

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma

René Bernards, Wilbert Zwart
2016-05-13

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Carsten Denkert, René Bernards, Ian J Majewski, Valentina Guarneri, Emilio Bria, Sherene Loi, Pierfranco Conte
2016-05-12

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Christine Desmedt, Carsten Denkert, René Bernards, Marielle Hijmans, Heikki Joensuu, Roderick L Beijersbergen, Patrick Neven, Gordon B. Mills, Wouter Nijkamp, Katrien Berns, Theo A Knijnenburg, Lodewyk F A Wessels, Bastiaan Evers
2016-04-25

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes

René Bernards, Roderick L Beijersbergen, Wipawadee Grernrum, Bastiaan Evers
2016-04-01

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Arianna Fumagalli, Federica Di Nicolantonio, René Bernards, Jonne Raaijmakers, Nizar El-Murr, David G. Mollevi, Mariangela Russo, Alberto Bardelli, René H. Medema, Alice Bartolini, Roderick L Beijersbergen, Cor Lieftink, Lodewyk F A Wessels
2016-02-01

DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

René Bernards
2016-09-15

Targeting the RB-E2F pathway in breast cancer

Ultan McDermott, René Bernards
2016-01-05

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer

Carlos Caldas, Tycho Bismeijer, Thierry Dubois, Magali Michaut, Suet-feung Chin, Ultan McDermott, William M Gallagher, René Bernards, Karin Jirström, Ian J Majewski, Darran P O'Connor, Oscar M Rueda, Lodewyk F A Wessels, Helen A Bardwell, Elena Provenzano, Astrid Bosma, Lorenza Mittempergher, Tesa M Severson, Justine K Peeters, Philip C Schouten, Roelof J C Kluin, Mireille H Snel, Jettie J F Muris, Sabine Linn
2016-03-22

Equivalence of MammaPrint array types in clinical trials and diagnostics

Bob Chan, René Bernards, Annuska Glas
2016-08-01

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Suzette Delaloge, René Bernards, Giuseppe Viale, Sherene Loi, Emiel Rutgers, Peter Vuylsteke
2016-06-01

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling

Olli-Pekka Kallioniemi, René Bernards, Disha Malani, Kimmo Porkka, Jose A Martinez-Climent
2015-04-21

A price to pay for tumor regression

René Bernards

Human - wd:Q20518809

Welcome to Inventaire

the library of your friends and communities

learn more